Docosanol

Summary

Docosanol (CHEMBL1200453) is an approved small-molecule antiviral drug (ATC D06BB11); indicated across 2 conditions including viral infectious disease and herpes simplex infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D06BB11
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 326.6 Da · C22H46O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200453
Name	Docosanol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	12620
ChEBI	CHEBI:31000
ATC	D06BB11
Molecular formula	C22H46O
Molecular weight	326.6
InChIKey	NOPFSRXAKWQILS-UHFFFAOYSA-N

SMILES: CCCCCCCCCCCCCCCCCCCCCCO

IUPAC name: docosan-1-ol

ChEBI definition: A long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It is a non-prescription medicine approved by the FDA to shorten healing time of cold sores.

Pharmacological roles (ChEBI): antiviral drug.

Other ChEBI roles (chemical / environmental): plant metabolite.

Also known as: Abreva, Behenic alcohol, Behenyl alcohol, Docosanol, Lidakol, N-docosanol, NSC-8407, Stenol 1822, DOCOSANOL, SID29215293, tadenan, SID174006877

Patent coverage: 12,494 distinct patent families (34,829 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
herpes simplex infectious disease	2	MONDO:0004609	EFO:1002022

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00467662	PHASE4	UNKNOWN	Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)
NCT04893577	PHASE2	COMPLETED	EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
NCT06558838	PHASE2	COMPLETED	Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).